{"entity":{"id":"hospices-civils-de-lyon","kind":"institution","name":"Hospices Civils de Lyon (HCL)","aka":["HCL","CHU de Lyon","Lyon University Hospital"],"tldr":"Lyon's university hospital group of 13 public hospitals, whose biostatistics service co-produces France's national cancer estimates and whose lung physicians co-lead the national lung screening pilot.","summary":"The Hospices Civils de Lyon describe themselves as 13 public hospitals covering every medical and surgical discipline, the university hospital of Lyon bound by agreement to the Université Claude Bernard Lyon 1, with an institute of cancer care among their divisions. Their hospitals include Édouard Herriot, Lyon Sud and the Croix-Rousse.\n\nThe HCL matter to French cancer statistics out of proportion to their size: their biostatistics service is one of the four partners, with Santé publique France, the Francim registry network and INCa, that model national incidence and survival from the local registries. INCa names Professor Sébastien Couraud of the HCL as co-coordinator, with Professor Marie-Pierre Revel of the Paris public hospitals, of IMPULSION, the national lung cancer screening pilot that opened to participants in May 2026, and Hôpital Lyon Sud is one of its two registered sites. The HCL are also the sponsor of several French trials held in OnCo, including TUMORAPA and TROPHIMMUN.","asOf":"2026-11-03","links":[{"label":"Hospices Civils de Lyon (French)","url":"https://www.chu-lyon.fr"},{"label":"IMPULSION on ClinicalTrials.gov","url":"https://clinicaltrials.gov/study/NCT07513818"}],"tags":[],"related":["ansm"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-leon-berard","sante-publique-france"],"pathways":[],"terms":[],"trials":["impulsion","tumorapa","trophimmun"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lyon","country":"FR","lat":45.761,"lng":4.832,"institutionType":"hospital","website":"https://www.chu-lyon.fr","university":"Université Claude Bernard Lyon 1","programs":["Institut de cancérologie des HCL","Biostatistics for the national cancer estimates","IMPULSION lung screening pilot (co-coordination)"]},"route":"/institutions/hospices-civils-de-lyon/","neighbours":{"institution":[{"id":"ansm","kind":"institution","name":"Agence nationale de sécurité du médicament et des produits de santé (ANSM)","route":"/institutions/ansm/"},{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/"},{"id":"sante-publique-france","kind":"institution","name":"Santé publique France","route":"/institutions/sante-publique-france/"}],"trial":[{"id":"impulsion","kind":"trial","name":"IMPULSION (national lung cancer screening pilot)","route":"/trials/impulsion/"},{"id":"trophimmun","kind":"trial","name":"TROPHIMMUN","route":"/trials/trophimmun/"},{"id":"tumorapa","kind":"trial","name":"TUMORAPA (switching from a calcineurin inhibitor to sirolimus after a transplant skin cancer)","route":"/trials/tumorapa/"}],"paper":[{"id":"paper-lapotre-ledoux-incidence-france-2023-beh","kind":"paper","name":"Incidence of the main cancers in metropolitan France in 2023 and trends since 1990","route":"/key-papers/paper-lapotre-ledoux-incidence-france-2023-beh/"},{"id":"paper-pfmg2025-genomic-medicine-france-lancet-reg-health-eur-2025","kind":"paper","name":"PFMG2025: integrating genomic medicine into the national healthcare system in France","route":"/key-papers/paper-pfmg2025-genomic-medicine-france-lancet-reg-health-eur-2025/"}]}}